Claire Friedman discusses the factors clinicians should consider when determining an immunotherapy treatment plan for older patients.
Claire Friedman, MD, Memorial Sloan Kettering Cancer Center, discusses considerations to take when planning immunotherapy treatments for older patients. There is also the possibility of combinations to consider.
When choosing an appropriate immunotherapy agent for an older patient, clinicians should discuss the different options, and their risks and benefits, with patients. Clinicians should keep several factors in mind. Not only are a patient’s lifestyle and medical history important, but so is their social support.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
September 11th 2024This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.